Covid and Fungus – Home › Forums › Immunotherapy › Expectations for therapy › nivolumab › Reply To: nivolumab
		October 3, 2017 at 6:55 pm
		
		#4190
		
		
		
	
The prescribing information indicates until disease progression or unacceptable toxicity. The interpretation of these criteria varies from institution to institution and from provider to provider
